Your browser doesn't support javascript.
[Clinical progress of neutralizing antibodies against SARS-CoV-2].
Wang, Yue; Yan, Jinghua; Shi, Rui.
  • Wang Y; Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
  • Yan J; Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
  • Shi R; Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Sheng Wu Gong Cheng Xue Bao ; 38(6): 2061-2068, 2022 Jun 25.
Article in Chinese | MEDLINE | ID: covidwho-1912221
ABSTRACT
Since the palivizumab for respiratory syncytial virus was approved in 1998, therapeutic antibodies against infectious diseases have been widely used in clinical treatment. Since the outbreak of COVID-19, plenty of neutralizing antibodies were developed and transferred into clinical trials, holding enormous promise for the treatment of COVID-19 under the context of emergency use authorization. This review summarizes the clinical progress of these drugs, in order to provide a reference for the research and development of neutralizing antibody drugs for the future.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Prognostic study Limits: Humans Language: Chinese Journal: Sheng Wu Gong Cheng Xue Bao Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: J.cjb.220118

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Prognostic study Limits: Humans Language: Chinese Journal: Sheng Wu Gong Cheng Xue Bao Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: J.cjb.220118